Anticancer Agent “Remitoro Intravenous Drip Infusion 300 microgram” (Denileukin Diftitox (Genetical Recombination)) Launched in Japan
Tokyo, May 19, 2021 – (JCN Newswire via SEAPRWire.com) – Eisai Co., Ltd. announced today that it has launched the anticancer agent “Remitoro® for Intravenous Drip Infusion 300μg” (Denileukin Diftitox (Genetical Recombination)) with the indications of relapsed or refractory Peripheral T-cell Lymphoma (PTCL) and relapsed or refractory Cutaneous T-cell Lymphoma (CTCL), in Japan. Eisai obtained... » read more